Evidence map›Paper›PMID 40599194›Full record

ArticleJournal of the advanced practitioner in oncology2025

Integrating a Rare Disease into Practice: Development of a Toolkit for Systemic Mastocytosis.

Sandra Kurtin, Cem Akin, Tracey I George, Edward Pearson

Abstract read
In one paragraph

Article in Journal of the advanced practitioner in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sandra KurtinFrom University of Arizona Cancer Center, Tucson, Arizona.
Cem AkinUniversity of Michigan, Ann Arbor Michigan.
Tracey I GeorgeARUP Laboratories, Salt Lake City, Utah.
Edward PearsonTexas Oncology, Dallas, Texas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic mastocytosis (SM) exemplifies the diagnostic and management challenges associated with rare diseases, which often involve prolonged time to diagnosis, limited access to clinical experts, and persistent symptom burden. Advanced practitioners (APs) are increasingly responsible for the care of patients with rare and classical hematologic disorders. The Advanced Practitioner Society for Hematology and Oncology (APSHO) convened a multidisciplinary, AP-led steering committee to evaluate the AP role in managing SM, develop an online toolkit, and design surveys to identify best practices, unmet needs, and practical strategies for improving care for patients living with indolent systemic mastocytosis (ISM). The toolkit emphasizes early symptom recognition, integration of validated patient-reported outcome measures, and incorporation of disease-specific tools into clinical workflows and electronic medical records (EMRs). The emergence of targeted therapies, such as avapritinib for both advanced and indolent SM, has further highlighted the need for AP education on novel disease mechanisms and treatment strategies. This project demonstrates a replicable model for developing educational and clinical resources to support APs in managing rare diseases and improving patient-centered care.

Identifiers

PMID40599194
PMCPMC12207526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.